阿比特龙在「高危」和「低危」转移性激素敏感性前列腺癌中的应用
该研究为STAMPEDE试验的事后亚组分析,共评估901例M1患者,按LATITUDE标准分为低危428例(48%)和高危473例(52%)。与单用ADT相比,ADT+AAP在低危患者中显著改善OS(HR 0.66,95%CI 0.44-0.98)和FFS(HR 0.24,95%CI 0.17-0.33),低危与高危组间OS或FFS未见效应异质性。结论认为无论「风险」或「体积」分层如何,mHNPC男性均可从ADT+AAP中获得治疗获益。
要点
- 低危M1患者接受ADT+AAP较单用ADT显著改善OS(HR 0.66,95%CI 0.44-0.98)和FFS(HR 0.24,95%CI 0.17-0.33)。
- 低危与高危组间OS或FFS未见效应异质性。
- 低危OS获益的需治疗人数为高危的四倍,但其他终点未观察到此现象。
核心结论
- mHNPC男性无论按「风险」或「体积」分层,均可从ADT+AAP中获得治疗获益。
研究设计与样本
- 2017年STAMPEDE试验「阿比特龙比较」的事后亚组分析。
- M1患者按LATITUDE标准进行风险分层,探索性亚组分层纳入CHAARTED标准。
- 共评估901例M1 STAMPEDE患者,低危428例(48%),高危473例(52%)。
- 主要终点为总生存(OS),次要终点为无失败生存(FFS)。
- 采用标准Cox回归和Kaplan-Meier生存估计进行分析。
主要发现
- 低危患者接受ADT+AAP较单用ADT显著改善OS(HR 0.66,95%CI 0.44-0.98)。
- 低危患者接受ADT+AAP较单用ADT显著改善FFS(HR 0.24,95%CI 0.17-0.33)。
- 低危与高危组间OS或FFS未见效应异质性。
- 低危OS获益的需治疗人数为高危的四倍,但其他测量终点未观察到此现象。
关键数值与推荐
- 风险分层采用LATITUDE试验标准。
- 探索性亚组分层纳入CHAARTED标准。
临床怎么用
- 原文结论认为mHNPC男性无论「风险」或「体积」分层如何均可从ADT+AAP中获得治疗获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains uncertainty as to whether men with LATITUDE "low-risk" M1 disease benefit from androgen deprivation therapy (ADT) combined with abiraterone acetate and prednisolone (AAP). OBJECTIVE: Evaluation of heterogeneity of effect between LATITUDE high- and low-risk M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial. DESIGN, SETTING, AND PARTICIPANTS: A post hoc subgroup analysis of the 2017 STAMPEDE "abiraterone comparison". Staging scans for M1 patients contemporaneously randomised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind to treatment assignment. Stratification was by risk according to the criteria set out in the LATITUDE trial. Exploratory subgroup stratification incorporated the CHAARTED criteria. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome measure was overall survival (OS) and the secondary outcome measure was failure-free survival (FFS). Further exploratory analysis evaluated clinical skeletal-related events, progression-free survival (PFS), and prostate cancer-specific death. Standard Cox-regression and Kaplan-Meier survival estimates were employed for analysis. RESULTS AND LIMITATIONS: A total of 901 M1 STAMPEDE patients were evaluated after exclusions. Of the patients, 428 (48%) were identified as having a low risk and 473 (52%) a high risk. Patients receiving ADT + AAP had significantly improved OS (low-risk hazard ratio [HR]: 0.66, 95% confidence interval or CI [0.44-0.98]) and FFS (low-risk HR: 0.24, 95% CI [0.17-0.33]) compared with ADT alone. Heterogeneity of effect was not seen between low- and high-risk groups for OS or FFS. For OS benefit in low risk, the number needed to treat was four times greater than that for high risk. However, this was not observed for the other measured endpoints. CONCLUSIONS: Men with mHNPC gain treatment benefit from ADT + AAP irrespective of risk stratification for "risk" or "volume". PATIENT SUMMARY: Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
引用
- Hoyle AP, Ali A, James ND, et al. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2019. PMID: 31447077. doi:10.1016/j.eururo.2019.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。